Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22083577 | 0.83 | DRD2 (0.44) | DRD2LGALS3FOLH1OPRM1 | |
| SCHEMBL25495603 | 0.83 | DGAT1 (0.36) | F2RL1OPRM1 | |
| SCHEMBL25900322 | 0.81 | LGALS3 (0.39) | LGALS3F2RL1FOLH1OPRM1PLK1 | |
| SCHEMBL25982998 | 0.81 | LGALS3 (0.38) | DRD2LGALS3F2RL1DRD4DRD3 | |
| SCHEMBL25979356 | 0.81 | LGALS3 (0.35) | DRD2LGALS3F2RL1DRD4DRD3 | |
| SCHEMBL25835937 | 0.81 | DRD2 (0.42) | DRD2LGALS3FOLH1OPRM1 | |
| SCHEMBL25495188 | 0.80 | LGALS3 (0.50) | LGALS3OPRM1 | |
| SCHEMBL25523201 | 0.80 | LGALS3 (0.44) | LGALS3F2RL1OPRM1 | |
| SCHEMBL17480080 | 0.78 | CA12 (0.34) | — | |
| SCHEMBL24894530 | 0.78 | EPHX2 (0.47) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | DRD2 1929/4885LGALS3 293/4885F2RL1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.